Canaccord Genuity Reiterates a 'Buy' on Momenta Pharmaceuticals (MNTA); Case on Inequitable Conduct Credible, but Legal Hurdle Still High
Tweet Send to a Friend
Canaccord Genuity reiterates a 'Buy' on Momenta Pharmaceuticals (NASDAQ: MNTA), PT $27.
Canaccord analyst, Ritu Baral, said, "Reiterate rating and ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Canaccord analyst, Ritu Baral, said, "Reiterate rating and ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
